Corium
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $2.0m | Grant | |
$16.0m | Series B | ||
Total Funding | €16.4m |
Recent News about Corium
EditStratagent Life Sciences is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders. The company aims to provide clinicians with essential treatment options that benefit patients, their families, and caregivers. Stratagent Life Sciences operates in the healthcare sector, specifically targeting CNS conditions, which include a range of neurological and psychiatric disorders. The company's business model revolves around the research, development, and subsequent commercialization of innovative CNS therapies. Revenue is generated through the sale of these therapies, primarily to healthcare providers and institutions. The company also engages in partnerships and collaborations to enhance its product offerings and market reach.
Keywords: CNS therapies, biopharmaceutical, commercialization, neurological disorders, psychiatric disorders, healthcare, treatment options, clinicians, patients, caregivers.